<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">By comparison, there are much fewer studies with mRNA-mAb delivery against infectious diseases. As the field advances, it will be important to utilize the information coming out of these studies to advance new approaches and to better define the pathway for development.</p>
